ArticleCancer medicine2026
Prognostic Significance of Secondary-Type Mutations in NPM1-Mutated Acute Myeloid Leukemia.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
NPM1 is among the most frequently mutated genes in acute myeloid leukemia (AML), and NPM1-mutated AML is generally associated with a favorable prognosis. However, substantial prognostic heterogeneity exists within this population. The prognostic significance of secondary-type mutations (STMs) in NPM1-mutated AML remains controversial. In this retrospective study of 179 patients with NPM1-mutated AML, the prognostic effects of age, common comutations, and STMs were evaluated. Multivariate analysis revealed that age ≥ 60 years and the presence of FLT3-ITD mutations were independently associated with poor overall survival (OS). Patients with NPM1/FLT3-ITD/DNMT3A triple mutations had the shortest median OS among the molecular subgroups examined. The treatment response did not differ significantly between STM-positive and STM-negative patients. No statistically significant association between STM status and OS was observed in the overall cohort or in exploratory subgroup analyses stratified by ELN 2022 risk category and age. Sensitivity analyses accounting for stem cell transplantation and untreated patients yielded similar results. Given the limited number of STM-positive patients, larger studies are needed to further clarify the prognostic significance of STMs in NPM1-mutated AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.